Want to see HK:6990 full AI Analyst Report?
Top Page
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
(6990)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$444.00
▼(-14.62% Downside)
Action:Reiterated
Date:09/23/26
The score is primarily supported by improving financial performance (TTM rebound to profitability, strong cash flow improvement, and a low-leverage balance sheet). This is offset by very weak valuation (P/E 762.1) and only neutral-to-soft technicals (negative MACD and price below the 50-day average), keeping the overall score in the mid range.
Positive Factors
Revenue Growth
The sharp TTM revenue increase indicates stronger commercial momentum and expanding demand for the company’s biopharmaceutical portfolio. If sustained, this growth can improve operating leverage, support continued research investment, and strengthen the company’s ability to build a larger revenue base over the next several quarters.
Negative Factors
Unproven Operating Profitability
Despite the TTM revenue and net income rebound, negative EBIT and thin EBITDA show that the core operating model has not yet demonstrated consistent profitability. Until revenue growth translates into durable operating earnings, future results remain more sensitive to spending levels and commercialization execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sharp TTM revenue increase indicates stronger commercial momentum and expanding demand for the company’s biopharmaceutical portfolio. If sustained, this growth can improve operating leverage, support continued research investment, and strengthen the company’s ability to build a larger revenue base over the next several quarters.
Read all positive factors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$101.54B
Dividend YieldN/A
Average Volume (3M)664.78K
Price to Earnings (P/E)653.4
Beta (1Y)0.64
Revenue Growth43.88%
EPS GrowthN/A
CountryHK
Employees2,300
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.55
Shares Outstanding176,822,250
10 Day Avg. Volume942,432
30 Day Avg. Volume664,777
Financial Highlights & Ratios
PEG Ratio-5.55
Price to Book (P/B)16.74
Price to Sales (P/S)39.59
P/FCF Ratio-265.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$619.63Price Target Upside19.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)0.3
Revenue Forecast (FY)HK$2.61B
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the Pe...
How the Company Makes Money
The company makes money primarily through (1) commercialization of its approved products (if applicable at the time of reporting) by selling biopharmaceuticals to hospitals, pharmacies, distributors and/or other healthcare channels, generating pro...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.20B | 2.06B | 1.93B | 1.54B | 803.93M | 31.79M |
| Gross Profit | 1.64B | 1.48B | 1.27B | 759.18M | 527.11M | -10.93M |
| EBITDA | 81.93M | -249.23M | -47.36M | -308.31M | -351.19M | -775.80M |
| Net Income | 126.87M | -381.97M | -266.77M | -574.13M | -616.10M | -875.26M |
Balance Sheet | ||||||
| Total Assets | 6.32B | 5.99B | 4.27B | 3.51B | 993.14M | 996.97M |
| Cash, Cash Equivalents and Short-Term Investments | 4.77B | 4.56B | 3.08B | 2.53B | 117.54M | 100.31M |
| Total Debt | 81.35M | 88.44M | 126.75M | 59.92M | 3.01B | 2.93B |
| Total Liabilities | 984.87M | 1.12B | 959.34M | 1.18B | 4.22B | 4.24B |
| Stockholders Equity | 5.34B | 4.87B | 3.31B | 2.33B | -3.21B | -3.24B |
Cash Flow | ||||||
| Free Cash Flow | 431.95M | -306.55M | -510.89M | -22.69M | -309.84M | -609.73M |
| Operating Cash Flow | 551.52M | -180.30M | -429.77M | 59.56M | -270.85M | -517.18M |
| Investing Cash Flow | -736.44M | 411.01M | -822.00M | -1.03B | -32.15M | -92.84M |
| Financing Cash Flow | -64.89M | 1.73B | 1.04B | 2.38B | 313.45M | 675.92M |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Technical Analysis
Negative
520.00
Price Trends
475.44
Negative
477.42
Negative
458.00
Negative
Market Momentum
-9.21
Positive
39.42
Neutral
4.66
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6990, the sentiment is Negative. The current price of 520 is above the 20-day moving average (MA) of 454.27, above the 50-day MA of 475.44, and above the 200-day MA of 458.00, indicating a bearish trend. The MACD of -9.21 indicates Positive momentum. The RSI at 39.42 is Neutral, neither overbought nor oversold. The STOCH value of 4.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6990.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% | |
63 Neutral | HK$139.32B | 95.59 | 6.06% | ― | 42.64% | 9.67% | |
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
59 Neutral | HK$101.54B | 653.42 | 2.43% | ― | 43.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$76.70B | -66.50 | -10.86% | ― | 42.47% | -15.80% | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
HK:6990
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
424.80
-26.40
-5.85%
HK:1801
Innovent Biologics
79.75
-10.45
-11.59%
HK:2269
Wuxi Biologics (Cayman)
44.48
8.86
24.87%
HK:9926
Akeso, Inc.
81.50
-36.80
-31.11%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.44
-42.85%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.04
-29.00%
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Corporate Events
Kelun-Biotech Seeks New Lung Cancer Indication for Core ADC sac-TMT After Strong Phase 3 Data
Oct 27, 2026
Sichuan Kelun-Biotech Biopharmaceutical announced that China’s National Medical Products Administration has accepted a new indication application for its core TROP2-directed ADC sacituzumab tirumotecan. The filing seeks approval for sac-TMT ...
Kelun-Biotech’s ADC Combo Shows Breakthrough Benefit in First-Line Lung Cancer
Oct 25, 2026
Sichuan Kelun-Biotech Biopharmaceutical, a Chinese oncology-focused drug developer, specializes in innovative antibody-drug conjugates that target solid tumors such as non-small cell lung cancer. Its lead assets include the TROP2-directed ADC saci...
Kelun-Biotech Advances Ultra-Long-Acting Asthma Antibody Into Phase 3 After Positive Data
Sep 8, 2026
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a China-based biopharma focused on innovative biologics, is co-developing SKB378/WIN378, an ultra-long-acting monoclonal antibody against TSLP for asthma, together with Windward Bio and Harbour Bi...
Kelun-Biotech Swings to Profit as Core Cancer Drug sac-TMT Gains Ground
Aug 17, 2026
Sichuan Kelun-Biotech reported interim 2026 results showing revenue of RMB978.3 million, up 2.9% year on year, and a sharp swing to a profit of RMB388.0 million from a loss a year earlier, supported by an 11.7% rise in gross profit and stronger ca...
Kelun-Biotech Sets August Board Meeting and Global Webcast for 2026 Interim Results
Aug 5, 2026
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has scheduled a board meeting for 17 August 2026 to review and approve its interim results for the six months ended 30 June 2026, alongside other corporate matters. The timing underscores the compa...
Kelun-Biotech Boosts Bank of China Structured Deposits to RMB1.1 Billion
Aug 4, 2026
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has entered into a third structured deposit agreement with Bank of China, subscribing to a principal-guaranteed product with a floating return valued at RMB400 million. Following this latest subscr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.